How much does a box of Jisandai/Bingtonsha cost after medical insurance in 2025?

Epclusa is one of the broadest-spectrum and simplest first-line oral antiviral regimens currently available for the treatment of hepatitis C ( HCV). Its indications cover adult patients with chronic hepatitis C genotypes 1 to 6, regardless of whether they are combined with compensated cirrhosis. The drug is an original anti-hepatitis C compound preparation developed by Gilead Sciences in the United States. It consists of 400 mg Sofosbuvir and 100 mg Velpatasvir. Taking one tablet daily for 12 weeks can completely eliminate the virus (reach SVR) in most patients. Because it does not rely on genotyping, does not need to be combined with interferon, has a fixed dosage cycle, and is well tolerated, Jisandai has quickly become the standard treatment for chronic hepatitis C in many countries around the world.

In mainland China, Jisandai has been officially approved for marketing in recent years and has been included in the national medical insurance drug catalog. At present, a common domestic specification is a box of 28 tablets (, the drug content of a single box is "400mg + 100mg" compound tablets. After the medical insurance negotiation, the price has been significantly reduced, and the market price is about 3,300 yuan per box. In some areas, due to local medical insurance Policies vary slightly. The actual out-of-pocket amount after inclusion in medical insurance varies depending on factors such as the patient’s status, medical insurance payment ratio, and whether the patient is in the Category B category. If the patient is eligible for the National Hepatitis C Prevention and Control Special Fund or local public welfare assistance project, the financial burden may be further reduced.

It should be noted that although Jisandai is a medical insurance drug, it must be diagnosed by a doctor as chronic hepatitis C, and relevant virology and liver function assessments must be completed before it can be prescribed. In addition, drug purchases may need to be made at hospital pharmacies or formal platforms to ensure compliance with drug sources and reimbursement procedures. For patients with hepatitis C, early diagnosis and early treatment are key, and Jisandai has become an important turning point in the global treatment of chronic hepatitis C due to its superior therapeutic effect and wide adaptability to the population.

Reference: https://www.epclusa.com/